These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31055186)

  • 1. Involvement of the ADAMTS13-VWF axis in acute Kawasaki disease and effects of intravenous immunoglobulin.
    Tsujii N; Nogami K; Matsumoto M; Yoshizawa H; Takase T; Tanaka I; Sakai T; Fukuda K; Hayakawa M; Sakai K; Isonishi A; Matsuura K; Fujimura Y; Shima M
    Thromb Res; 2019 Jul; 179():1-10. PubMed ID: 31055186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.
    Kubo M; Sakai K; Hayakawa M; Kashiwagi H; Yagi H; Seki Y; Hasegawa A; Tanaka H; Amano I; Tomiyama Y; Matsumoto M
    J Thromb Haemost; 2022 Jul; 20(7):1589-1598. PubMed ID: 35352474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
    Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
    BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.
    Horii M; Uemura S; Uemura M; Matsumoto M; Ishizashi H; Imagawa K; Iwama H; Takeda Y; Kawata H; Nakajima T; Fujimura Y; Saito Y
    Heart Vessels; 2008 Sep; 23(5):301-7. PubMed ID: 18810578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease.
    Sakurai Y; Takatsuka H; Onaka M; Takada M; Nishino M
    Int Arch Allergy Immunol; 2014; 165(2):111-8. PubMed ID: 25401215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
    Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood group antigen A on von Willebrand factor is more protective against ADAMTS13 cleavage than antigens B and H.
    Hayakawa M; Kato S; Matsui T; Sakai K; Fujimura Y; Matsumoto M
    J Thromb Haemost; 2019 Jun; 17(6):975-983. PubMed ID: 30929293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis.
    Morioka C; Uemura M; Matsuyama T; Matsumoto M; Kato S; Ishikawa M; Ishizashi H; Fujimoto M; Sawai M; Yoshida M; Mitoro A; Yamao J; Tsujimoto T; Yoshiji H; Urizono Y; Hata M; Nishino K; Okuchi K; Fujimura Y; Fukui H
    Scand J Gastroenterol; 2008; 43(11):1387-96. PubMed ID: 18609162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
    Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Von Willebrand factor parameters as potential biomarkers for disease activity and coronary artery lesion in patients with Kawasaki disease.
    Jakob A; Schachinger E; Klau S; Lehner A; Ulrich S; Stiller B; Zieger B
    Eur J Pediatr; 2020 Mar; 179(3):377-384. PubMed ID: 31760507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
    Murphy SJX; Lim ST; Hickey F; Kinsella JA; Smith DR; Tierney S; Egan B; Feeley TM; Murphy SM; Collins DR; Coughlan T; O'Neill D; Harbison JA; Madhavan P; O'Neill SM; Colgan MP; O'Donnell JS; O'Sullivan JM; Hamilton G; McCabe DJH
    Thromb Haemost; 2021 Jan; 121(1):86-97. PubMed ID: 32932544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis.
    Asada S; Namisaki T; Kaji K; Takaya H; Kubo T; Akahane T; Kawaratani H; Nishimura N; Takeda S; Masuda H; Shibamoto A; Inoue T; Iwai S; Tomooka F; Tsuji Y; Fujinaga Y; Kitagawa K; Mitoro A; Sato S; Matsumoto M; Yoshiji H
    Dig Dis Sci; 2024 Mar; 69(3):851-869. PubMed ID: 38244124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
    Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
    J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
    Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases.
    Ko S; Okano E; Kanehiro H; Matsumoto M; Ishizashi H; Uemura M; Fujimura Y; Tanaka K; Nakajima Y
    Liver Transpl; 2006 May; 12(5):859-69. PubMed ID: 16528712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
    Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
    Tse SM; Silverman ED; McCrindle BW; Yeung RS
    J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress.
    Matsumoto M; Kawaguchi S; Ishizashi H; Yagi H; Iida J; Sakaki T; Fujimura Y
    Pathophysiol Haemost Thromb; 2005; 34(1):35-40. PubMed ID: 16293984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability.
    Takaya H; Namisaki T; Asada S; Iwai S; Kubo T; Suzuki J; Enomoto M; Tsuji Y; Fujinaga Y; Nishimura N; Sawada Y; Kaji K; Kawaratani H; Moriya K; Akahane T; Matsumoto M; Yoshiji H
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.